Samuel Reich joined SAB Biotherapeutics in 2021 after its combination with Big Cypress Acquisition Group, where he served as Chief Executive Officer, Chief Financial Officer, and a member of the board of directors. Then, Reich served as Executive Chairman of the SAB’s Board of Directors. Now he’s its Chief Executive Officer—but it’s not just him with a different title. Last year, his company rebranded as SAB BIO, as the company “transformed significantly” under his leadership.
The story checks out. Reich has helped the company hone its focus to address immunotherapy in the type 1 diabetes community, which he calls SAB BIO’s “singular focus.” In February, the company took a big step, as a Phase 1 trial of its SAB-142 drug to help human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes met its “primary objectives.”
Reich said, “With our initial study objectives met, we believe SAB-142 is now well-positioned to be a transformative therapy in autoimmunity by delaying the progression or onset of type 1 diabetes, and we look forward to advancing this product candidate into Phase 2b clinical development in 2025.”
This mission is just the latest for the graduate of the University of Pennsylvania School of Medicine, who’s no stranger to the C-Suite, having served in executive leadership roles for the better part of two decades. He was the founder of Acuity Pharmaceuticals, Biscayne Pharmaceuticals, and Biscayne Neurotherapeutics and is a Managing Member of The Reich Group, which provides early-stage investments in Biotech.
He also oversaw a major shift for SAB BIO toward sunnier skies—literally—as the company moved its headquarters from South Dakota to Miami, though the SD location still exists as a manufacturing facility. Reich said the burgeoning tech scene in Miami was part of the reason for the shift, as was the chance to recruit more in-office employees. There can be no denying that even sunnier times are ahead for the company—literally and figuratively.
